Skip to main content
. 2022 Jul 11;128(18):3319–3329. doi: 10.1002/cncr.34354

Figure 4.

Figure 4

Cumulative incidence of documented COVID‐19 infection or COVID‐19–related death: (A) COVID‐19 infection according to seroconversion status after the initial vaccination course; (B) COVID‐19–related death according to seroconversion status after the initial vaccination course; (C) COVID‐19 infection and (D) COVID‐19–related death in the subgroup (N = 110) with known seroconversion status after booster vaccination (regardless of seroconversion status after initial vaccination course); and (E) COVID‐19 infection and (F) COVID‐19–related death in the subgroup (N = 37) with negative seroconversion status after the booster vaccination according to the receipt of prophylactic tixagevimab/cilgavimab. The p values in A–D are from log‐rank tests stratified by age (younger or older than 65 years) and histology of the hematologic cancer; p values in E and F are from unstratified log‐rank tests. COVID‐19 indicates coronavirus disease 2019.